Clinical trial · Interventional
Prostatic Hyperplasia Treatment and Cancer Prevention
Treatment of Prostatic Hyperplasia With Topical Papaverine
NCT03064282CI-TRIAL-00050331unknownEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Treatment of patients with prostatic hyperplasia with topical papaverine.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostatic Hyperplasia | Benign Prostatic Hyperplasia | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| papaverine | Drug | — | UNRESOLVED |
| Placebo | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- Drug free base as placebo
- interventionNames
- Other: Placebo
- type
- EXPERIMENTAL
- label
- group two- papaverine arm
- description
- papaverine in a suitable base
- interventionNames
- Drug: papaverine
Primary outcomes (1)
- measure
- Laboratory tests to measure regression of symptoms
- timeFrame
- every 4 weeks up to 16 weeks
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 50 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * patients with symptoms e.g. obstructive voiding, hyperplasia and high PSA Exclusion Criteria: * patients on chemotherapy * abnormal lab values e.g. liver function, GFR and CAD
References
Publications (1)
- BACKGROUNDHafez B, Hafez ES. Andropause: endocrinology, erectile dysfunction, and prostate pathophysiology. Arch Androl. 2004 Mar-Apr;50(2):45-68. PMID 14761837